Bill > SB00191

This bill expands and extends the psychedelic-assisted therapy pilot program, which provides qualified patients with therapy using MDMA (3,4-methylenedioxymethamphetamine, a synthetic psychoactive drug also known as ecstasy or molly) or psilocybin (a naturally occurring substance found in some mushrooms). The program, to be administered by a medical school and overseen by the Department of Mental Health and Addiction Services, will now allow individuals aged eighteen and older to participate if they meet clinical eligibility criteria set by the medical school's institutional review board, in addition to being a resident of the state who is a veteran, retired first responder, or direct care healthcare worker. The program will operate as a research initiative approved by the federal Food and Drug Administration (FDA) and will be effective starting July 1, 2026.